Masoud Maher 4

What Happened

• Masoud Maher, President, CEO and a director of Maxcyte, was granted 300,000 restricted stock units (RSUs) and 600,000 derivative awards (option-based) on March 27, 2026. Both grants show an acquisition price of $0.00, meaning they were awarded as compensation rather than purchased (total cash paid = $0).
• These are compensation awards, not open-market purchases or sales, so they do not represent an immediate cash investment by the insider.

Key Details

• Transaction date: 2026-03-27; Form 4 filed: 2026-03-31.
• 300,000 RSUs (F1): each RSU converts to one share; 25% vests on March 27, 2027, then the remainder vests in three equal annual installments thereafter (i.e., typical four-year annual cliffs subject to continued service).
• 600,000 derivative awards (F2): 25% vests on March 27, 2027, then the remainder vests in 36 equal monthly installments thereafter (typical 4‑year schedule with monthly vesting after the first year).
• Price/value reported: $0.00 per share at grant (award compensation); no immediate proceeds to or from the insider.
• Shares owned after the transaction: not specified in the provided filing details.
• Filing timeliness: Form filed 3/31/2026 for the 3/27/2026 grant; the filing itself does not include a late-filing flag in the provided data.

Context

• These grants are standard equity compensation intended to align executive incentives with shareholder value and vest over multiple years contingent on continued service; they do not represent an immediate market purchase or sale.
• The 600,000 derivative award refers to option-like awards whose underlying shares vest over time; exercise (and any subsequent sale) would be a separate transaction and would appear on a future Form 4 if/when it occurs.
• For retail investors: award grants are common for executives and are informative about compensation and retention, but they are not the same signal as an insider buying shares with personal funds.